Burzynski Research Institute, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BZYR research report →
About the company
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name.
- CEO
- Stanislaw R. Burzynski
- IPO
- 1997
- Employees
- 1
- HQ
- Houston, TX, US
Price Chart
- Market Cap
- $525.79K
- P/E
- -0.41
- P/S
- 0.00
- P/B
- -7.81
- EV/EBITDA
- -0.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2073.54%
- ROIC
- 1911.08%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,386,207 · -3.80%
- EPS
- $-0.01 · -2.94%
- Op Income
- $-1,386,207
- FCF YoY
- 25.82%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.03
- Beta
- 0.37
- Avg Volume
- 13.28K
Get TickerSpark's AI analysis on BZYR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BZYR coverage
Recent articles, reports, and earnings notes.
No research on BZYR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BZYR report →Similar companies
Peers in the same neighborhood.